408 related articles for article (PubMed ID: 15801017)
1. Anti-lipoprotein lipase antibody in systemic sclerosis: association with elevated serum triglyceride concentrations.
Kodera M; Hayakawa I; Komura K; Yanaba K; Hasegawa M; Takehara K; Sato S
J Rheumatol; 2005 Apr; 32(4):629-36. PubMed ID: 15801017
[TBL] [Abstract][Full Text] [Related]
2. Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus.
Reichlin M; Fesmire J; Quintero-Del-Rio AI; Wolfson-Reichlin M
Arthritis Rheum; 2002 Nov; 46(11):2957-63. PubMed ID: 12428237
[TBL] [Abstract][Full Text] [Related]
3. Anti-p53 autoantibody in systemic sclerosis: association with limited cutaneous systemic sclerosis.
Hara T; Ogawa F; Muroi E; Komura K; Takenaka M; Hasegawa M; Fujimoto M; Sato S
J Rheumatol; 2008 Mar; 35(3):451-7. PubMed ID: 18203319
[TBL] [Abstract][Full Text] [Related]
4. Autoantibody against peroxiredoxin I, an antioxidant enzyme, in patients with systemic sclerosis: possible association with oxidative stress.
Iwata Y; Ogawa F; Komura K; Muroi E; Hara T; Shimizu K; Hasegawa M; Fujimoto M; Tomita Y; Sato S
Rheumatology (Oxford); 2007 May; 46(5):790-5. PubMed ID: 17309887
[TBL] [Abstract][Full Text] [Related]
5. Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus?
de Carvalho JF; Borba EF; Viana VS; Bueno C; Leon EP; Bonfá E
Arthritis Rheum; 2004 Nov; 50(11):3610-5. PubMed ID: 15529371
[TBL] [Abstract][Full Text] [Related]
6. Decreased levels of autoantibody against histone deacetylase 3 in patients with systemic sclerosis.
Kuwatsuka Y; Ogawa F; Iwata Y; Komura K; Muroi E; Hara T; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
Autoimmunity; 2009 Feb; 42(2):120-5. PubMed ID: 19021012
[TBL] [Abstract][Full Text] [Related]
7. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis.
Sato S; Fujimoto M; Hasegawa M; Komura K; Yanaba K; Hayakawa I; Matsushita T; Takehara K
Rheumatology (Oxford); 2004 Oct; 43(10):1261-6. PubMed ID: 15266059
[TBL] [Abstract][Full Text] [Related]
8. Circulating anticentromere CENP-A and CENP-B antibodies in patients with diffuse and limited systemic sclerosis, systemic lupus erythematosus, and rheumatoid arthritis.
Russo K; Hoch S; Dima C; Varga J; Teodorescu M
J Rheumatol; 2000 Jan; 27(1):142-8. PubMed ID: 10648030
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis.
Fujii H; Shimada Y; Hasegawa M; Takehara K; Sato S
J Dermatol Sci; 2004 Jun; 35(1):43-51. PubMed ID: 15194146
[TBL] [Abstract][Full Text] [Related]
10. Serum concentrations of the CXC chemokines interleukin 8 and growth-regulated oncogene-alpha are elevated in patients with systemic sclerosis.
Furuse S; Fujii H; Kaburagi Y; Fujimoto M; Hasegawa M; Takehara K; Sato S
J Rheumatol; 2003 Jul; 30(7):1524-8. PubMed ID: 12858452
[TBL] [Abstract][Full Text] [Related]
11. Anti-agalactosyl IgG antibodies in sera from patients with systemic sclerosis.
Nishijima C; Sato S; Takehara K
J Rheumatol; 2001 Aug; 28(8):1847-51. PubMed ID: 11508588
[TBL] [Abstract][Full Text] [Related]
12. OxLDL/beta2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis, and antiphospholipid syndrome: pathogenic implications for vascular involvement.
Lopez LR; Simpson DF; Hurley BL; Matsuura E
Ann N Y Acad Sci; 2005 Jun; 1051():313-22. PubMed ID: 16126973
[TBL] [Abstract][Full Text] [Related]
13. Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1 and T cell intracytoplasmic antigen 1-related protein in patients with rheumatic diseases: increased prevalence in systemic lupus erythematosus and systemic sclerosis and correlation with clinical features.
Jimenez-Boj E; Kedersha N; Tohidast-Akrad M; Karlhofer FM; Stummvoll G; Zimmermann C; Ulrich W; Guiducci S; Hoefler E; Aringer M; Schett G; Matucci-Cerinic M; Smolen JS; Steiner G
Arthritis Rheum; 2008 May; 58(5):1226-36. PubMed ID: 18438838
[TBL] [Abstract][Full Text] [Related]
14. Increased cutaneous T-cell-attracting chemokine levels in sera from patients with systemic sclerosis.
Hayakawa I; Hasegawa M; Matsushita T; Yanaba K; Kodera M; Komura K; Takehara K; Sato S
Rheumatology (Oxford); 2005 Jul; 44(7):873-8. PubMed ID: 15797972
[TBL] [Abstract][Full Text] [Related]
15. Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis.
Nishijima C; Hayakawa I; Matsushita T; Komura K; Hasegawa M; Takehara K; Sato S
Clin Exp Immunol; 2004 Nov; 138(2):357-63. PubMed ID: 15498049
[TBL] [Abstract][Full Text] [Related]
16. Autoantibodies against calpastatin in sera from patients with systemic sclerosis.
Sato S; Hasegawa M; Nagaoka T; Takamatsu Y; Yazawa N; Ihn H; Kikuchi K; Takehara K
J Rheumatol; 1998 Nov; 25(11):2135-9. PubMed ID: 9818655
[TBL] [Abstract][Full Text] [Related]
17. Anti-DNA topoisomerase II alpha autoantibodies in Japanese patients with systemic sclerosis.
Hayakawa I; Hasegawa M; Takehara K; Sato S
Arch Dermatol Res; 2005 Oct; 297(4):180-3. PubMed ID: 16180014
[TBL] [Abstract][Full Text] [Related]
18. Elevation of serum lymphotactin levels in patients with systemic sclerosis.
Muroi E; Ogawa F; Shimizu K; Komura K; Hasegawa M; Fujimoto M; Sato S
J Rheumatol; 2008 May; 35(5):834-8. PubMed ID: 18322986
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of soluble CD31 in patients with systemic sclerosis (SSc): association with limited cutaneous SSc.
Sato S; Komura K; Hasegawa M; Fujimoto M; Takehara K
J Rheumatol; 2001 Nov; 28(11):2460-5. PubMed ID: 11708419
[TBL] [Abstract][Full Text] [Related]
20. Anti-DNA topoisomerase IIalpha autoantibodies in localized scleroderma.
Hayakawa I; Hasegawa M; Takehara K; Sato S
Arthritis Rheum; 2004 Jan; 50(1):227-32. PubMed ID: 14730620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]